Germany
· Delayed Price · Currency is EUR CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of EUR 618.03 million. The enterprise value is 449.87 million.
| Market Cap | 618.03M |
| Enterprise Value | 449.87M |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +9.65% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 123.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.62 |
| EV / Sales | 6.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.39 |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.29 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.30% and return on invested capital (ROIC) is -32.31%.
| Return on Equity (ROE) | -54.30% |
| Return on Assets (ROA) | -24.52% |
| Return on Capital (ROIC) | -32.31% |
| Revenue Per Employee | 60,644 |
| Profits Per Employee | -256,381 |
| Employee Count | 1,172 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 13.43 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.96% in the last 52 weeks. The beta is 2.61, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 2.61 |
| 52-Week Price Change | -25.96% |
| 50-Day Moving Average | 2.67 |
| 200-Day Moving Average | 2.92 |
| Relative Strength Index (RSI) | 50.13 |
| Average Volume (20 Days) | 112,822 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.21 |
Income Statement
In the last 12 months, CureVac had revenue of EUR 65.86 million and -278.43 million in losses. Loss per share was -1.24.
| Revenue | 65.86M |
| Gross Profit | -86.28M |
| Operating Income | -285.64M |
| Pretax Income | -276.29M |
| Net Income | -278.43M |
| EBITDA | -270.34M |
| EBIT | -285.64M |
| Loss Per Share | -1.24 |
Balance Sheet
The company has 202.52 million in cash and 39.04 million in debt, giving a net cash position of 163.48 million.
| Cash & Cash Equivalents | 202.52M |
| Total Debt | 39.04M |
| Net Cash | 163.48M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 376.53M |
| Book Value Per Share | 1.68 |
| Working Capital | 141.57M |
Cash Flow
In the last 12 months, operating cash flow was -289.85 million and capital expenditures -33.59 million, giving a free cash flow of -323.44 million.
| Operating Cash Flow | -289.85M |
| Capital Expenditures | -33.59M |
| Free Cash Flow | -323.44M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -131.00% |
| Operating Margin | -433.71% |
| Pretax Margin | -419.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.65% |
| Shareholder Yield | -9.65% |
| Earnings Yield | -44.46% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of -1.94. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.94 |
| Piotroski F-Score | n/a |